Ipilimumab 3 mg/kg vs 10 mg/kg in Metastatic Melanoma
Jeffrey A. Sosman, MD, from the Vanderbilt-Ingram Cancer Center, discusses a trial comparing two doses of ipilimumab for patients with metastatic melanoma.
Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses a trial comparing two dosages of ipilimumab for patients with metastatic melanoma.
The trial, which compared 3 mg/kg and 10 mg/kg of ipilimumab, was completed quickly because of the high rate of patient accrual in Europe, Sosman says. At the time of the trial, ipilimumab had been approved in the U.S. but not in Europe.
Clinical Pearls
Sosman expects the results from this trial to reveal a sense of the toxicity difference between two doses of ipilimumab.
- A trial comparing 3 mg/kg of ipilimumab and 10 mg/kg of ipilimumab in patients with metastatic melanoma has been completed
- Patient accrual was completed quickly
- Data will reveal a sense of the toxicity difference between two doses of ipilimumab
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
